Inflection Biosciences: Michael O'Neill. Developing Innovative Cancer Therapeutics




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Inflection Biosciences: Michael O'Neill. Developing Innovative Cancer Therapeutics
Released on: August 15, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Michael O'Neill, Co-founder of Inflection Biosciences talks about the company's pipelines that include novel PIM kinase inhibitors and unique multi-targeting kinase inhibitors in preclinical development.
  • Summary
  • Transcript
  • Participants
  • Company
Michael O'Neill, Co-founder of Inflection Biosciences talks about the company's pipelines that include novel PIM kinase inhibitors and unique multi-targeting kinase inhibitors in preclinical development.
Michael O'Neill, Co-founder of Inflection Biosciences talks about the company's pipelines that include novel PIM kinase inhibitors and unique multi-targeting kinase inhibitors in preclinical development.
Michael O'Neill
Inflection Biosciences
Inflection Biosciences
Inflection Biosciences Ltd is an early stage, drug development company with a focus on discovering and developing innovative small molecule therapeutics addressing major unmet needs in cancer. Based in Dublin and London , Inflection Biosciences’ strategy is to find and license the best drug discovery projects from around the world and to progress them through pre-clinical and early clinical stages before seeking partners for later stage clinical development and commercialisation. Inflection Biosciences evaluates potential licensing candidates using the strictest criteria based on technical feasibility and commercial viability to ensure that chosen projects have the maximum likelihood of reaching development clinical milestones. We are committed to a rational, data-driven evidence based approach for final candidate selection. Licensing candidates are subjected to a rigorous testing regime to validate previous work and to identify essential differentiating factors against other early stage projects.